Geron (GERN) Stock Forecast & Price Target
Geron (GERN) Analyst Ratings
Bulls say
Geron Corp's positive outlook is primarily supported by the anticipated revenue growth from the recently approved Rytelo in the European Union, which is expected to begin generating income in 2026, with further potential expansion from an additional approval anticipated in the first half of 2025. The company’s strategic focus on educating healthcare providers and increasing awareness of Rytelo is likely to enhance its market penetration, especially in the treatment of low-risk myelodysplastic syndromes and relapsed/refractory myelofibrosis, potentially doubling the commercial opportunity. Moreover, the experience of key board members and the proactive management strategies reinforce confidence in Geron's ability to navigate the complexities of the oncology market and capitalize on the therapeutic benefits offered by Rytelo.
Bears say
Geron Corp's stock outlook is negatively impacted by a slowdown in the momentum of the Rytelo launch in lower-risk myelodysplastic syndromes, with management reporting flat revenue trends over recent months. The reliance on third-line patients for the majority of Rytelo prescriptions has resulted in disappointing uptake among second-line patients, which may delay revenue growth for several quarters. Furthermore, lowered peak sales projections for Rytelo from $1.2 billion to $1.0 billion reflect ongoing concerns about commercial competition and potential regulatory or clinical risks that could hinder the company's prospects.
This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares